4-chloro-2-(methoxymethyl)pyridine | 315493-76-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-chloro-2-(methoxymethyl)pyridine
• 英文别名: 4-Chloro-2-methoxymethylpyridine
• CAS: 315493-76-6
• 化学式: C₇H₈ClNO
• 分子量: 157.6
• InChiKey: ADAZNLUNVUZMCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chloro-2-(methoxymethyl)pyridine 生成 4-(6-chloronaphthalene-2-sulfonyl)-1-{[1-(2-methoxymethyl-pyridin-4-yl)-4-piperidinyl](methyl)amino}-2-piperazinone
  参考文献：
  名称：

  ACYLHYDRAZINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND USE THEREOF

  摘要：

  公开号：

  EP1188755B1
• 作为产物：
  描述：

  sodium methylate 、 4-氯-2-氯甲基吡啶盐酸盐 在 碳酸氢钠 作用下， 以 甲醇 为溶剂， 反应 17.0h， 以a title compound (0.28 g) was obtained as a tan oil的产率得到4-chloro-2-(methoxymethyl)pyridine
  参考文献：
  名称：

  Acylhydrazine derivatives, their production and use

  摘要：

  具有抑制活化血凝因子X抑制活性的新型酰肼衍生物，其为一般式(I)或其盐的化合物，其中R为可选取代的碳氢基团或可选取代的杂环基团；R1和R2分别为氢或可选取代的碳氢基团，或者R1和R2或X1的取代基和R2可以结合形成可选取代的环；X1和X2分别为自由价、可选取代的烷基或可选取代的亚胺基；D为氧或硫；A为-N(R3)-Y-或-N═Y-，其中R3为氢、可选取代的碳氢基团或酰基；Y为可选取代的链烃基团或可选取代的环状基团；Z为(1)可选取代的氨基、(2)可选取代的亚氨基或(3)可选取代的含氮杂环基团。

  公开号：

  US06723722B1

文献信息

• 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis
  申请人：Tsubouchi Hidetsugu

  公开号：US20080119478A1

  公开（公告）日：2008-05-22

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: (1) in the above formula (1), R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R1 and —(CH2) n R2 may form a spiro ring represented by the formula (30) below, together with the adjacent carbon atom (in the formula below, RRR represents a piperidyl group which may have substituents on the piperidine ring), (30) and R2 represents a benzothiazolyloxy group, quinolyloxy group, pyridyloxy group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis , multi-drug-resistant Mycobacterium tuberculosis , and atypical acid-fast bacteria.

  本发明提供了一种由下述通式（1）表示的2,3-二氢-6-硝基咪唑[2,1-b]噁唑化合物： 在上述式（1）中，R1代表氢原子或C1-C6烷基，n代表0到6的整数，R1和—(CH2)nR2可以与相邻的碳原子形成如下式（30）所示的螺环，其中，在下式中，RRR代表可能在哌啶环上具有取代基的哌啶基： （30）且R2代表苯并噻唑氧基、喹啉氧基、吡啶氧基或类似基团。该化合物对结核分枝杆菌、多重耐药结核分枝杆菌和非典型酸杆菌具有优异的杀菌作用。
• NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF
  申请人：FUJIWARA Hideyasu

  公开号：US20130116430A1

  公开（公告）日：2013-05-09

  An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl group, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R 3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R 4 and R 5 each independently represent a hydrogen atom; and R 2 and R 4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

  本发明的目的是提供一种具有优异的Syk抑制活性的化合物和制药组合物。本发明提供了一种由以下式(I)表示的烟酰胺衍生物（其中R1表示卤素原子；R2表示C1-12烷基、C2-12烯基、C2-12炔基、C3-8环烷基、芳基、芳基-C1-6烷基或杂环基，每种均可选地具有至少一个取代基；R3表示芳基或杂环基，每种均可选地具有至少一个取代基；R4和R5各自独立地表示氢原子；且R2和R4可以与它们结合的氮原子一起形成具有至少一个取代基的环状氨基团）或其盐，并且用于治疗Syk相关疾病的制药组合物包括该烟酰胺衍生物或其盐。
• 7-N-Heterocyclyl cephalosporins, a process for preparing and a pharmaceutical composition comprising the same
  申请人：Merck & Co., Inc.

  公开号：EP0018595A2

  公开（公告）日：1980-11-12

  Disclosed are antibiotic cephalosporins (I) of the formula : Wherein the stylized radical attached to the 7-amino nitrogen of the cephalosporin moiety represents a nitrogen-containing heterocyclic group (mono- or polycyclic); R is, inter alia, hydrogen, alkyl, heterocyclylalkyl, aryl, alkenyl, aralkyl, -NR2, -OR, COOR, CONR2 or CN; A is conventionally known in the cephalosporin art; and R2 is H, or loweralkoxyl; X is S, 0, CH2, or NR7 (R7 is, interalia, hydrogen, alkyl or aralkyl. Also disclosed are the pharmaceutically acceptable salt and ester derivatives of processes for the preparation of such compounds; and pharmaceutical compositions comprising such compounds.

  本发明公开了式......的抗生素头孢菌素（I）： 其中，与头孢菌素分子的 7-氨基氮相连的定型基代表含氮杂环基团（单环或多环）；R是氢、烷基、杂环烷基、芳基、烯基、芳烷基、-NR2、-OR、COOR、CONR2或CN；A是头孢菌素技术中已知的；R2是H或低级烷氧基；X是S、0、CH2或NR7（R7是氢、烷基或芳烷基）。还公开了制备此类化合物的工艺的药学上可接受的盐和酯衍生物；以及包含此类化合物的药物组合物。
• NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF
  申请人：FUJIFILM Corporation

  公开号：EP2589592B1

  公开（公告）日：2018-08-22
• 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP1678185B1

  公开（公告）日：2008-10-08